| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI helps detect diseases more accurately and quickly in medical images, leading to earlier diagnosis and better treatment for patients. |
Technology Acceptance Model (TAM) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
AI in radiology provides diagnostic support by acting as a second opinion, helping radiologists detect abnormalities with greater accuracy and confidence. |
Clinical Decision Support System (CDSS) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy means having the knowledge to understand how AI works, its applications, and its impact on society. |
Technological Pedagogical Content Knowledge (TPACK) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
Factors influencing AI acceptability include trust, system understanding, integration with workflows, and openness to technology—not superficial aspects like machine color. |
the Technology Acceptance Model (TAM) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
When respected colleagues or institutions support AI, healthcare professionals are more likely to accept and use it. |
Unified Theory of Acceptance and Use of Technology (UTAUT) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
A common perceived threat of AI in healthcare is that it may eventually replace certain roles, leading to job insecurity among healthcare professionals. |
the concept of Technological Displacement |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Human-centred AI systems are designed to support, not replace, medical professionals, making them more comfortable and willing to use the technology. |
Human-Centered Design Theory |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The “system usage” category refers to practical aspects of how AI fits into the healthcare environment—like its value, efficiency, and ease of integration into existing clinical workflows.
|
the Technology Acceptance Model (TAM) and Human-Technology Interaction frameworks |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Healthcare professionals are more likely to accept AI if it aligns with their ethical standards and supports patient-centered care. |
Value-Based Adoption Model (VAM) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
Acceptability depends on how well AI fits workflows and user needs, beyond just economic or technical aspects. |
Technology Acceptance Model (TAM) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
In Parkinson’s disease, dopamine-producing neurons in the brain are lost. Human embryonic stem cells can be used to generate new dopamine neurons to restore brain function. |
Cell Replacement Therapy |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
he STEM-PD product, a human embryonic stem cell-derived therapy for Parkinson's disease, was tested for safety and efficacy in rats |
Clinical and Translational Report |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
The most accurate information available states the preclinical safety study for STEM-PD in rats lasted 39 weeks. This specific duration is important because it refers to a Good Laboratory Practice (GLP) study. GLP studies are rigorous, regulated studies designed to thoroughly test a new treatment's safety before it can be used in humans. The 39-week duration allowed researchers to closely monitor the rats for any long-term side effects, the potential for tumors, and where the transplanted cells ended up in the body. The finding of no adverse effects over this extended period was crucial for moving forward with human trials. |
pharmacological and toxicological safety assessment |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
This trial is designed to assess the safety and tolerability of transplanting STEM-PD cells into the brains of patients with moderate Parkinson's disease. |
STEM-PD Trial |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under non-GMP conditions |
|
The STEM-PD product is manufactured under GMP (Good Manufacturing Practice)-compliant conditions to ensure safety, consistency, and quality for human use. This includes strict control of the lab environment, raw materials, production steps, and final testing — all required before clinical trials. |
GMP in Cell Therapy Manufacturing |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
the cells maintained long-term at the site of transplantation without any signs of distribution to other parts of the body, toxicity, or tumor formation, according to stem-pd.org. |
STEM-PD trial |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells increased cognitive impairments. |
|
In Parkinson's disease, the brain loses dopamine-producing neurons, which leads to motor symptoms like tremors, stiffness, and difficulty with movement. STEM-PD is a treatment strategy that involves transplanting stem cells designed to replace these lost neurons.
The key finding in efficacy studies of STEM-PD in rats is that the transplanted cells successfully improved the motor symptoms that these rats, which had been given Parkinson's-like symptoms, were experiencing. This indicates that the new dopamine-producing cells were able to integrate into the brain and start functioning, helping to restore normal movement. |
cell replacement therapy |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
For STEM-PD batches, which aim to generate dopamine neurons for Parkinson's disease treatment, key markers used to assess the purity and identity of the progenitors in vitro before transplantation commonly include LMX1A, FOXA2, and OTX2. |
Developmental Neurobiology that focusing on the Molecular and Genetic Mechanisms of Midbrain Dopaminergic Neuron Development. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b is a signaling molecule that plays a critical role in the development of the midbrain, particularly the ventral midbrain, where dopaminergic neurons are located. In the context of STEM-PD, FGF8b is used to promote the differentiation of stem cells into dopaminergic neuron precursors. It does this by activating specific signaling pathways that regulate gene expression and cell fate determination.SHH is another morphogen that is essential for the development of the ventral midbrain and the differentiation of dopaminergic neurons. It works in conjunction with FGF8b to guide the proper development of these neurons. SHH signaling can also enhance the survival and function of dopaminergic neurons, making it a valuable factor in STEM-PD manufacturing. |
directed differentiation of pluripotent stem cells, which is fundamentally rooted in developmental biology |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
In preclinical trials for Parkinson's disease, researchers create animal models (like rats) that exhibit symptoms similar to human Parkinson's patients, specifically issues with movement (motor deficits). The primary goal of a treatment like STEM-PD is to alleviate these symptoms. Therefore, a successful outcome is demonstrated when the treated animals show a noticeable improvement in their ability to move, coordinate, and perform tasks that were difficult before treatment. This directly addresses the main clinical problem in Parkinson's disease. |
cell replacement therapy |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|